Raise Awareness

Explorando las terapias complementarias y la medicina funcional en el cuidado del Parkinson 

masaje

La medicina integrativa combina la medicina basada en la evidencia con terapias complementarias de eficacia comprobada y la medicina funcional; tratamiento que pretende atender a la persona en su totalidad, para controlar los síntomas de la enfermedad de Parkinson (EP). Explore cómo los tratamientos no farmacológicos, como los masajes, la acupuntura, la terapia con luz roja y el CBD, se utilizan a veces para favorecer el bienestar junto con los cuidados tradicionales del Parkinson. 

El siguiente artículo se basa en una de las Charlas con Expertos - Expert Briefings  de la Parkinson's Foundation, que explora las terapias complementarias y la medicina holística en el cuidado del Parkinson, presentada por la Dra. Britt Stone, profesora clínica adjunta, división de Trastornos del Movimiento, Departamento de Neurología en el Vanderbilt University Medical Center (VUMC, por sus siglas en inglés), un Centro de Excelencia de la Parkinson's Foundation y directora de operaciones clínicas para las clínicas de neurología del campus principal de VUMC. 

Un puente entre la medicina moderna y los cuidados complementarios 

Las terapias tradicionales de medicina occidental incluyen los cuidados que pueda recetar su neurólogo, ya sea levodopa u otros medicamentos recetados, fisioterapia o terapia ocupacional o psiquiatría o la recomendación de un asistente de salud a domicilio. 

La medicina integrativa combina la medicina con terapias complementarias de eficacia probada para fomentar un bienestar óptimo.  

  • La medicina funcional se engloba dentro de la medicina integrativa; busca identificar la causa raíz de la enfermedad y tratar a la persona en su totalidad mediante un plan de atención personalizado.  

  • Las terapias complementarias son un elemento de la medicina funcional: pueden incluir atención plena (mindfulness), terapia artística o de danza u otros tratamientos. 

Una mirada más profunda a la medicina funcional 

Vivir bien con Parkinson requiere un manejo continuo: los medicamentos adecuados, ejercicio estructurado, una dieta equilibrada y la capacidad de adaptarse a las necesidades cambiantes. La medicina funcional también adopta un enfoque integral de la atención, haciendo hincapié en factores constantes de nutrición, salud intestinal y estilo de vida

En esencia, la medicina funcional incorpora a la vida diaria hábitos, rutinas y ritmos que contribuyen a la salud general. A partir de ahí, las terapias específicas para atender las necesidades individuales se integran en un plan de cuidados. Éstos pueden incluir ejercicios adaptados, suplementos, hierbas medicinales u otras terapias complementarias.  

La medicina funcional también puede incluir pruebas de laboratorio o diagnósticas para descubrir si factores como la genética o la exposición ambiental, incluidos los alérgenos, influyen en el funcionamiento del organismo. Las pruebas de laboratorio, que no siempre cubre el seguro, podrían incluir la detección de moho ambiental u otras toxinas en el organismo o evaluaciones de:  

  • Niveles de vitaminas y minerales 

  • Salud intestinal 

  • Marcadores inflamatorios 

  • Sensibilidad alimentaria 

Hasta cierto punto, la genética, el medio ambiente, las enfermedades previas y los factores sociales y de conducta influyen en los resultados de la salud de cada persona. La medicina funcional toma en cuenta todos estos aspectos y busca ralentizar la progresión de la enfermedad y optimizar la calidad de vida. 

Terapias complementarias 

El Parkinson puede causar diversos síntomas no motores, como rigidez, dolor, ansiedad, sueño y cambios de humor, y es posible que los medicamentos no los alivien todos. Las terapias complementarias no farmacológicas se han ido generalizando para el tratamiento de los síntomas del Parkinson, sobre todo para aquellos que no responden tan bien a los medicamentos recetados. 

Ciertas terapias complementarias que fomentan las conexiones sociales y la creatividad al tiempo que promueven el propósito y el juego han demostrado mejorar la calidad de vida. Un metaanálisis de 2020 demostró que el baile mejoraba los síntomas motores y no motores y la calidad de vida en personas con Parkinson. Un programa de seis semanas de arteterapia con barro para Parkinson mostró una disminución de la depresión, el estrés y el pensamiento obsesivo-compulsivo entre los participantes.  

Algunas terapias complementarias están basadas en la filosofía y la medicina chinas y en el concepto de chi o qi, la energía o fuerza vital que anima a una persona. Se cree que un chi lento o deficiente provoca enfermedades. El trabajo de respiración mente-cuerpo, como el Tai Chi y el qigong, utilizados para mejorar el equilibrio, el funcionamiento y el estado de ánimo en el Parkinson, busca mejorar el flujo de energía. 

Hay otras terapias como: 

Acupuntura: Un estudio demostró que la acupuntura, que también busca equilibrar el flujo de energía, podría aliviar el dolor musculoesquelético en el Parkinson. Otros informes de casos y estudios clínicos muestran que la acupuntura puede mejorar las actividades de la vida diaria de las personas con Parkinson. La punción seca, una técnica de fisioterapia utilizada para aliviar el dolor, acelerar la curación y mejorar el movimiento, también utiliza pequeñas agujas finas, pero la técnica es diferente y el objetivo es el tratamiento del músculo específico, en lugar de mejorar el flujo de energía. 

Masaje: Se utiliza para aumentar la relajación y aliviar los espasmos y calambres musculares. Una revisión de 2020 que analizaba 12 estudios acerca de la terapia de masaje y sus beneficios en el Parkinson descubrió que:  

  • Múltiples tipos de masaje inducían relajación. 

  • Los participantes reportaron mejoras en el estado de ánimo, la fatiga, el sueño y el dolor.  

  • Algunas investigaciones demuestran que los tipos de masaje neuromuscular, como el shiatsu, el tui na y el masaje neuromuscular tailandés, podrían mejorar los síntomas motores.   

Terapia de luz roja: Las nuevas investigaciones muestran que la terapia con luz roja de bajo nivel, también llamada fotobiomodulación, puede tener un potencial neuroprotector en el Parkinson. Sin embargo, se necesitan más estudios. Los beneficios potenciales para la salud de la terapia con luz roja fueron descubiertos por científicos de la NASA que, al experimentar con diodos emisores de luz para estimular el crecimiento de las plantas, observaron que las luces también aceleraban la cicatrización de las heridas.  

La terapia con luz roja se utiliza actualmente como parte de la terapia fotodinámica en dermatología para tratar ciertos tipos de cáncer de piel (la luz roja activa un fármaco fotosensibilizante). También se utiliza para tratar la psoriasis y el acné. Se cree que la terapia con luz roja actúa estimulando las mitocondrias de las células tratadas, lo que conduce a una actividad celular más eficaz y al crecimiento de nuevas células. Es importante proteger los ojos cuando se utiliza cualquier tipo de terapia con luz roja. 

Cannabidiol (CBD): Este compuesto se encuentra en las plantas de cannabis como cáñamo y marihuana e interactúa con el sistema endocannabinoide del organismo. Los receptores CB1 y CB2, componentes clave de este sistema, intervienen en la comunicación entre las células cerebrales y la salud intestinal e inmunitaria. 

En la marihuana, hay mayores concentraciones de THC, el compuesto que produce un efecto psicoactivo. El cáñamo suele ser rico en CBD, un compuesto que puede ser útil para el sueño, la ansiedad o el dolor, aunque se necesita más investigación. Epidiolex es una forma recetada de CBD, aprobada por la Food and Drug Administration (Administración de Alimentos y Medicamentos) para tratar ciertos tipos de convulsiones.  

La legalización  de la marihuana medicinal y recreativa varía según el estado. Puede haber consideraciones de seguridad, dependiendo de sus síntomas o de los medicamentos que esté tomando.  

Incorporación de la terapia complementaria a su rutina  

La creación de un plan personalizado y equilibrado para manejar el Parkinson puede ayudarle a mantener su independencia. Las terapias complementarias, el contacto terapéutico, un profesional que escuche, el tiempo de descanso y la atención plena pueden mejorar la calidad de vida y la sensación de bienestar.  

A la hora de decidir qué terapias podrían beneficiarle, piense en sus objetivos y en los síntomas que más le molestan. Mantenga una conversación abierta con su equipo de atención médica y analice las opciones de tratamiento disponibles. Hablar acerca de las posibles terapias con su doctor puede ayudarle a evitar posibles interacciones y garantizar los mejores resultados. Conectarse en línea o en persona con personas de la comunidad de Parkinson también puede darle la oportunidad de hablar acerca de lo que ha funcionado para otros y compartir sus propias experiencias.   

Considere terapias que se ajusten a sus necesidades y que además sean accesibles, asequibles y manejables. Añada un elemento nuevo, observe los efectos o beneficios y ajuste o cambie los planes, con la opinión de su equipo de atención médica, según sea necesario. 

Aprenda más  

Explore nuestros recursos acerca de las terapias complementarias y el manejo de los síntomas en el Parkinson:   

My PD Story

Karen and Mark at wedding
Care Partners

Karen Cyr-Condon

I first met my husband, Mark, in 2010, married in 2013, and on August 26, 2025, he passed away unexpectedly due to balance issues caused by his Parkinson’s disease (PD). In November 2010, we noticed a tremor in his hand while watching a performance of Jersey Boys on Broadway in New York.

Following this, Mark consulted his doctor and was initially diagnosed with benign essential tremors. He then researched further and sought the expertise of a leading neurologist in New England, receiving the shocking diagnosis of Parkinson’s disease. Until that point, throughout his 50 years he had enjoyed excellent health.

Three years later, we married in Kennebunkport, ME, at a venue called Hidden Pond, despite his PD. We believed we were prepared for the challenges of Parkinson’s, but true readiness is elusive until faced with adversity. Initially, we enjoyed life, traveling and spending quality time with family and friends. We planned for retirement by purchasing land in Kennebunkport and spending time at our condo in Naples, FL. Little did we know that the backyard of our wedding reception venue would become our dream retirement home. Life has a way of cracking back. 

Mark, my best friend and love of my life, was known for his wit, sense of fun and gentlemanly demeanor. He was incredibly kind and had a playful spirit. Let me share how he embodied all these qualities.

Karen and Mark with sunglasses on, smiling

Our love story inspired our wedding theme: the “Love Fest.” Our wedding reflected Mark’s elegance; he made me laugh daily with his humorous remarks and the sparkle in his eyes. He was lively and spirited, often dancing and singing karaoke in our living room. Even during car rides, he could shift from being upset one moment to bursting into song the next. He embraced my enthusiasm for New Year’s Eve, donning a festive hat, garland and noisemakers.

Mark was adventurous, though not in the traditional sense; he was spontaneous and would suggest late-night bowling on New Year’s Eve. During this time, we lived life to the fullest and Parkinson’s was a distant cousin. We were aware, took progressive measures, but did not let “it” control our daily lives. 

Over the years, we did our best to navigate Mark’s condition, including undergoing deep brain stimulation (DBS) surgery. This past summer, he was thrilled to have his device replaced with a new Abbott chargeable model with the help of Christipher Hennessey, Dr. Cosgrove and his Brigham and Women’s team. Despite the daily struggles with Parkinson’s, Mark remained resilient and rarely complained, and we cherished our love and life together. I was preparing for retirement, and we aimed to build a future that would allow us to enjoy a few more years before facing the advanced stages of Parkinson’s.

However, in the last two years, Mark encountered numerous challenges as his condition progressed. This summer, he grappled with balance issues, festination (or shuffling) and freezing episodes. We witnessed a decline, and I found myself unprepared for the emotional toll of being his caregiver.

One late Sunday afternoon, after returning home from a weekend in Kennebunkport, mile walks on the beach, seafood, family, card games and laughter, we were about to enjoy some takeout Chinese food. I called him outside to admire the tomatoes that had ripened over the weekend.

Moments later, I discovered him unresponsive on the ground. He had suffered a fracture of his top vertebra and passed away instantly. This was not the way it was supposed to end! But I’m sure in his mind it was; no pain, no stage four, and no burden on others. This was Mark. In my mind, I’m rejecting the loss of my husband and wanted to squeeze out a few more years. 

The date of his death certificate reads August 26, 2025; however, I believe the true date of his passing was August 24, 2025, as that was when all life departed from his body. A silver lining in this tragedy is that Mark, with his generous spirit, chose to be an organ donor. He gave two kidneys and one liver, which is why he remained on life support for two additional days.

Parkinson’s disease is a debilitating condition that robbed my best friend, Mark, of his spark but also affected me, our family members, and all who loved him. I miss him severely, and my life will never be the same. While I am saddened that we were so close to having the future we planned together, I also recognize that I was fortunate to share 15 wonderful years with Mark, years that many people may never experience in a lifetime.

Karen Cyr-Condon at marathon race

To honor Mark and the time we had together, I decided to raise Parkinson’s awareness and funds to end Parkinson’s and become a Parkinson’s Champion. I ran in the 2025 Manchester Half Marathon in Mark’s memory. I have run for 40 years but never has a run meant so much to me. This is not the end but a beginning in my fight against this ugly disease.

As an educator by trade, I will advocate and be a voice for people living with Parkinson’s and care partners. 

Parkinson’s Champions athletes raise funds and awareness for the Parkinson’s Foundation while competing in some of the world’s most popular endurance events. Become a Parkinson’s Champion today and explore our upcoming endurance events.

My PD Story

Wilma van de Berg
Researchers

Wilma van de Berg

2025 Trailblazer Award

Rethinking Lewy Bodies and Cellular Traffic in Parkinson’s Disease

In Parkinson’s disease (PD), it is believed that dopamine neurons break down in part due to internal buildup of disruptive clumps called Lewy bodies. These Lewy bodies contain many lipids, which make up membranes of cellular components, and proteins including a misfolded form of a protein called alpha-synuclein. While much research has focused on what damage Lewy bodies cause to cells after they are formed, we still do not fully understand what causes them to form in the first place.

Wilma van de Berg, PhD, recipient of a Parkinson’s Foundation Trailblazer Award, is piecing together what conditions lead to Lewy body formation in neurons. By better understanding how Lewy bodies form, researchers can design treatments and therapies that could prevent them from forming and fight PD progression.

“Our conceptually highly innovative research can potentially transform Lewy body research and contribute to the development of complementary strategies for currently lacking disease-modifying therapies in PD.” – Dr. van de Berg

Alpha-synuclein is involved in regulating the shuttling of signaling molecules like dopamine into and out of neurons. It does so by attaching to lipid membranes of vesicles, little enclosed packages optimized for transport.

Dr. van de Berg believes that PD causes a disruption in alpha-synuclein’s shuttling role at these membranes in cells, leading to traffic jams of vesicles and other proteins that then become Lewy bodies. She also theorizes that alpha-synuclein may misfold within developing Lewy bodies, rather than misfolded alpha-synuclein causing Lewy bodies, a novel perspective.

To test this hypothesis, Dr. van de Berg, senior postdoc Dr. Tim Moors (Co-PI) and their team at the VU University Medical Center in Amsterdam, Netherlands, will first analyze postmortem brain tissue samples from people who did and did not have PD. They expect to see lower levels of critical shuttling regulation proteins in PD-affected neurons compared to non-PD neurons.

Next, Dr. van de Berg’s team will use neuron-like cells in petri dishes to see if deactivating cell shuttling signals (forcing a cellular traffic jam) leads to Lewy body formation. This could further confirm her hypothesis, especially if it leads to natural alpha-synuclein misfolding as well.

Dr. van de Berg’s team will also test a treatment involving PARP-1 inhibitors, intended to “loosen up” this traffic jam, to see if it can improve the health of those petri dish neurons with Lewy bodies. These experiments could set the foundation for future PD treatment development centered on this new understanding of Lewy body formation.

“The development of alternative and complementary hypotheses for Lewy body formation, their exploration in model systems, and their translation to patient-relevant materials are urgently needed,” said Dr. van de Berg. “I am really excited that I will be able to test our hypothesis and hope to contribute to novel therapeutics in the PD field.”

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

My PD Story

Heba Deraz, MD, PhD Headshot
Researchers

Heba Deraz, MD, PhD

2024 Melvin Yahr Parkinson’s Disease Clinical Research Award

How Lying Down Could Counter the Risks of Standing Up in Parkinson’s

People with Parkinson’s disease (PD) often experience disruptions related to the autonomic nervous system, which regulates all the “automatic” bodily functions. One of these affected functions is blood pressure, which can cause those with PD to develop a condition called neurogenic orthostatic hypotension (nOH). This condition creates bouts of low blood pressure after standing, which can lead to dizziness or fainting.

Heba Deraz, MD, PhD, recipient of the 2024 Melvin Yahr Parkinson’s Disease Clinical Research Award, jointly awarded by the Parkinson’s Foundation and the International Association of Parkinsonism and Related Disorders (IAPRD), believes that a potential solution to nOH could be prescribed periods of lying down.

“This research aims to improve the understanding of orthostatic hypotension in Parkinson’s disease, a common but underrecognized source of disability. By identifying clinical patterns, it could lead to earlier detection and more targeted interventions.” – Dr. Deraz

In contrast to nOH, supine hypertension (SH) is when blood pressure increases when lying down. Dr. Deraz theorizes that regularly lying down, increasing blood pressure, will counterbalance the low blood pressure episodes of nOH when standing up. The difficulty is that sustained SH can also be a health hazard, so finding the right ratio of lying down to standing to maximize safety and relief is key.

Working in the lab of Dr. Alberto Espay at the University of Cincinnati, Dr. Deraz will enlist the help of 60 people living with PD to test her hypothesis. Each will be equipped with 24-hour blood pressure monitoring devices which will capture bouts of decreased blood pressure from standing, as well as increased blood pressure from lying down. This data will be collected over several weeks, during which Dr. Deraz and her team will assess each person’s quality of life and nOH severity through routine questionnaires.

At the end of the experiment, Dr. Deraz expects to see that those with a greater number of SH episodes relative to nOH episodes have increased quality of life and reduced blood pressure problems when standing. These results could inform practical medical guidance for those with PD and nOH, offering relief from this hazardous condition by simply optimizing time spent lying down.

As a neurologist who works with many people with PD in her medical practice at Cairo University Hospitals in Egypt, Dr. Deraz knows firsthand what the impacts of such a study would mean for the PD community.

“This support motivates me to build a career dedicated to improving understanding and treatment of these often-overlooked autonomic dysfunction symptoms,” said Dr. Deraz. “Ultimately, this work could contribute to a broader focus on autonomic dysfunction as a key component of Parkinson’s care and research.”

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

Raise Awareness

Celebrating 12 Milestones that Defined 2025

🧠 What will you learn in this article?

This article highlights the ways the Parkinson’s Foundation helped people living with Parkinson’s and the Parkinson’s community in 2025. It highlights:

  • How we advanced research through funding grants and evolving our genetics study. 
  • Funded local community programs.
  • Launched new policy effort to improve care and research through advocacy.
  • Spread Parkinson’s awareness through programs, campaigns and resources.

2025 was a remarkable year for the Parkinson’s Foundation. Over the course of 365 days, we advanced Parkinson’s disease (PD) research while working hard to represent the one million people in the U.S. living with this neurodegenerative disease. We strengthened our connections among care partners and everyone serving the PD community.  

With your support, we launched new initiatives and vital PD resources, stayed fast in our commitment to improving PD care and research, and empowering the community through education and new resources.  

accomplishments

Thanks to YOU, here are the top 12 ways we made a difference this year:

1. Awarded more than $4.3 million in high-risk, high-reward research.

In a year when federal funding for disease research sharply declined, we significantly increased our investment in Parkinson’s research. We awarded more than $4.3 million across 44 grants. We are proud to fund scientists pursuing innovative studies across diverse areas of PD — driving the development of new therapies, treatments and ultimately a cure for the 10 million people worldwide living with this neurological disease.

Explore our ongoing research

Meet Jeff Kim, PhD

2025 Parkinson’s Foundation Postdoctural Fellow

Dr. Kim is leveraging AI (artificial intelligence) to advance genetics research. His research seeks to understand how overlapping PD mutations may influence the risk of developing PD. 

Jeff Kim at lab

2. Reached 30,000+ participants in our genetics study.

PD gene

In 2025, PD GENEration: Powered by the Parkinson’s Foundation reached unprecedented numbers including: 

  • Providing genetic testing and counseling to 30,000+ people with Parkinson’s, at no cost.

  • Finding that approximately 12-13% of participants carry a genetic link to PD.

  • Expanded study to a total of 77 testing sites worldwide and counting — adding sites in Mexico, Colombia, Chile, Peru and El Salvador.

We also launched an exciting new pilot program, PD Trial Navigator, to help advance PD GENEration’s goal of accelerating genetic-focused clinical trials. This program helps inform PD GENEration participants about Parkinson’s genetic trials they may qualify for based on their genetic results.

Enroll Now in PD GENEration

3. Launched new policy effort to accelerate PD treatments and care.

Andi Lipstein Fristedt

In 2025, we launched new policy initiatives aiming to empower the PD community through advocacy. Highlights include:

Sign up for our emails to keep up to date with advocacy efforts

4. Funded local Parkinson’s programs in 38 states.

parkinsons exercise program

We awarded more than $1 million in community grants for programs that help people living with PD across 38 states. Our 2025 grants fund local programs that provide exercise and educational support for people with PD and their care partners and address mental health needs. Since 2011, the Foundation has devoted more than $12.7 million in community-based programs, reaching a combined 81,000 people with PD and care partners.

 Pictured: Parkinson’s Foundation Community Grantee, Parkinson's Exercise Program For You, in Dana Point, CA, offers PD-tailored exercise programs. 

To find your nearest exercise or wellness class, visit your local chapter’s webpage or call our Helpline at 1-800-4PD-INFO (1-800-473-4636).

5. Appointed our first-ever Chief Medical Officer.

Headshot of Sneha Mantri, MD, MS

This year, we welcomed Sneha Mantri, MD, MS, as Chief Medical Officer of the Parkinson’s Foundation. A nationally recognized movement disorders specialist and educator, Dr. Mantri believes in getting to know her patients and personalizing their treatments. “I'm excited to bring that philosophy of care to this role and address the needs of people with Parkinson’s on a national scale,” she said.

Look out for virtual events featuring Dr. Mantri in 2026.

Learn more about Dr. Mantri here

6. Moved two Parkinson’s Virtual Biotech drugs into trials.

Parkinson’s Virtual Biotech is a research-driven investment fund we support alongside Parkinson’s UK. In 2025 we shared two exciting advances:

  • Project ASPro-PD became the first Parkinson’s Virtual Biotech project to enter a large phase 3 trial, assessing whether ambroxol (a common cough medicine ingredient) can slow the progression of Parkinson’s. This trial is the closest to delivering a new treatment.

  • A new drug from NRG Therapeutics, designed to repair the mitochondria that power brain cells, is advancing to clinical trials for Parkinson’s and ALS (amyotrophic lateral sclerosis). This progress was made possible through early investment from the Parkinson’s Virtual Biotech, proving how our venture philanthropy model fuels innovation — turning bold ideas into real possibilities for people living with Parkinson’s and making investments less risky for future funders.

Learn more about the Parkinson’s Virtual Biotech

7. Launched new resources to help people optimize their PD care.

We know that healthcare appointments for Parkinson’s can feel overwhelming. Which is why we published new content and tips dedicated to help people with PD and care partners advocate for their best care. Use our Steps to Prepare for a Parkinson’s Appointment worksheet for a step-by-step guide to choosing your top three appointment topics. 

Learn how to optimize your Parkinson’s care

8. Raised $263,000 on Parkinson’s Foundation Day of Giving.

day of giving

Our incredible community came together and made our third annual Day of Giving the most successful so far, raising double the amount raised in 2024. Our steadfast supporters made this special day a success, raising awareness and funds to support our mission to make life better for people with Parkinson’s disease.

Give today

9. Facilitated 3,949 community service hours through Parkinson’s Ambassadors.

Etana Soloman and her mother

Volunteers are essential to our mission and help us localize our reach. This year, we trained 239 new Parkinson’s Foundation Ambassadors and brought all our volunteers together at our national Volunteer Leadership Summit.

Etana Soloman joined our People with Parkinson’s Advisory Council to add her voice and help represent young caregivers and people like her mother who are in the later stages of PD. “Being able to care for my mom is truly an honor”  Read her story.

Find a volunteer opportunity near you

10. Reached 8.6 million visits to Parkinson.org and expanded Spanish-language engagement.

Parkinson.org reached a record of 8.6 million visits, including 1.3 million visits to our Spanish content. Every page visit represents an opportunity to connect people with life-changing resources, digital events and actionable ways to help make life better for people with Parkinson’s.

Hispanic and Latino members of the PD community face distinct barriers to living well with Parkinson’s. In 2025, we published new Spanish pages on dementia, caregiving, vertigo, depression, hospital safety and more (explore these pages in English, too: dementia, caregiving, vertigo, depression, hospital safety).

Explore our Spanish pages

Visit Parkinson.org now

11. 20,000 participants raised more than $8.3 million through community fundraising events.

Brooke Ramsey and family

Parkinson’s Foundation community fundraisers raised an impressive $8.3 million to advance PD research, access to care and life-changing resources in 2025. Together, every person who participates in Moving Day, A Walk for Parkinson’s, Parkinson’s Champion and Parkinson’s Revolution bring us closer to a cure.

Two years after his diagnosis, Brooke Ramsey found Moving Day Columbus. For the last 14 years his family has raised more than $117,000 to help make life better for people with Parkinson’s. Read his story.

Find a Moving Day near you

Become a Parkinson’s Champions

Join us for Parkinson’s Revolution

12. Engaged with our audience through two awareness campaigns.

In April, we introduced the world to PAM, your guide to Parkinson’s Awareness Month. To raise PD awareness, PAM shared essential information, tips and resources about PD on our social media channels and website.

Hi! I'm Pam!

In April we: 

  • Posted 5 new videos highlighting PD facts everyone should know.
  • Reached 2+ million visits to Parkinson.org — our most page views in a single month!
  • Earned 914,000 impressions across our social media posts

Follow us on social media to help spread Parkinson’s awareness

In November, for National Family Caregivers Month, we amplified the diverse experiences of caregiving through our Real Care. Anywhere. campaign. We provided tailored resources for three types of caregivers including those caring for someone living with Parkinson’s, those providing care from a distance and those managing PD alone.

Explore our care partner resources

 

We are setting bold goals for 2026 to create an even greater impact on the Parkinson’s community — and your support makes it possible.

Donate today

Advancing Research

Meet a Researcher Working to Make Adaptive DBS More Effective

🧠 What will you learn in this article?

This article highlights ongoing research aimed at improving the effectiveness of adaptive deep brain stimulation. It discusses: 

  • The definition of adaptive DBS (aDBS). 

  • Adaptive deep brain stimulation and how it can alleviate Parkinson’s symptoms. 

  • Research into whether “entrained-gamma” signals may make adaptive deep brain stimulation more effective than the “beta” signals currently used in the treatment. 

  • How this research could improve the lives of people with Parkinson’s. 

Lauren Hammer headshot

Over time, Parkinson’s disease (PD) medications can begin to lose their effectiveness. When this happens, deep brain stimulation (DBS) can be a promising treatment option for certain candidates. For DBS, electrodes are implanted into the brain that deliver controlled electrical stimulation that counteracts PD symptoms. 

Most DBS systems are designed to deliver consistent stimulation based on settings set and updated by physicians. However, a newer version called adaptive DBS (aDBS), recently approved by the U.S. Food and Drug Administration (FDA) for clinical use, monitors brain signals associated with PD symptoms in real time and adjusts stimulation automatically. This ability to auto-adjust stimulation has the potential to enhance DBS efficiency and minimize side effects, improving quality of life for those that use it.

Adaptive DBS (aDBS) monitors brain signals associated with Parkinson’s symptoms in real time and automatically adjusts DBS stimulation.

Lauren Hammer, MD, PhD, recipient of a Parkinson’s Foundation Stanley Fahn Junior Faculty Award, is working to make aDBS even more effective by determining which types of brain signals offer the best information on how to adjust stimulation in response to symptoms. Current aDBS technology monitors low-frequency brain waves called “beta” signals, but Dr. Hammer believes that higher frequency “entrained-gamma” signals may be better for predicting and controlling PD symptoms. 

Learn more about DBS

 “This research aims to advance deep brain stimulation for Parkinson’s disease by identifying the most effective neural signal to guide adaptive DBS,” said Dr. Hammer. “Results could support expanding the set of neural signals used for clinical aDBS, enabling more effective and personalized treatment.” 

From her lab at the University of Pennsylvania, a Parkinson’s Foundation Center of Excellence, Dr. Hammer will first run an in-laboratory assessment where people with PD perform various movement tasks while their brain signals are monitored. This will provide data as to which type of signal — beta or entrained-gamma — offers a more accurate reflection for when PD symptoms like involuntary movements are occurring. 

Dr. Hammer will then take a small group of people with DBS for PD and upgrade them to aDBS for an at-home study. After participants are programmed for aDBS stimulation using both beta signals and entrained-gamma signals, they will switch weekly between these settings, recording how well their symptoms are controlled at home.   

At the end of the trial, Dr. Hammer and her team will have data to suggest which signal type guided the best aDBS experience for different types of people with PD.  

 “I’m deeply grateful to the Parkinson's Foundation for investing in early-career scientists and accelerating progress toward better care and a cure.” – Dr. Hammer 

“Receiving this Parkinson’s Foundation award is an incredible honor and an important milestone in my journey to improve the lives of people with Parkinson’s disease,” said Dr. Hammer. “As a new faculty member starting my own laboratory, this support comes at a critical time — helping me build the foundation for a research program focused on developing next-generation deep brain stimulation therapies. Funding at this early stage is vital to turning promising ideas into impactful treatments, and this award will help bridge the gap between training and long-term research support.” 

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

My PD Story

Colum MacKinnon, PhD Headshot
Researchers

Colum MacKinnon, PhD

2025 Impact Award 

Investigating New Ways to Address Posture Impairment in Parkinson’s 

A common symptom of Parkinson’s disease (PD) is impaired posture. Unfortunately, this symptom is resistant to standard dopamine replacement therapies, and not much is known about the neurological mechanisms that lead to it. Left unchecked, posture impairment can lead to serious falls and other injuries for people with PD. 

Colum MacKinnon, PhD, recipient of a Parkinson’s Foundation Impact Award, suspects that PD affects brainstem neurons responsible for sending posture-related signals to the muscles of the legs and feet. Investigating this potential mechanism behind PD-related posture impairment may contribute to future treatments that could alleviate this debilitating symptom. 

“If successful, this work will be the first to demonstrate that brainstem pathways that control muscle firing properties are altered in people with PD and are associated with postural impairment.” – Dr. MacKinnon 

Dr. MacKinnon, with the help of his coinvestigators Dr. Laura McPherson, PT, DPT, PhD, and Dr. Daniel Free, PhD, will enroll people with and without PD, recording and analyzing their posture and gait (walking manner). He will also use a device to measure muscle activity activity as they point and flex their feet, capturing nerve signals important for balance and posture. 

From this initial data collection, Dr. MacKinnon expects to see reduced postural muscle activity that is controlled by descending brainstem systems in people with PD, and this reduction will correlate with impaired posture and walking ability. 

Next, Dr. MacKinnon will use a noninvasive vagus nerve stimulation device, commonly used to treat migraines and cluster headaches, to stimulate neurons within the brainstem associated with postural control. If his hypothesis is correct, this stimulation will temporarily improve the posture and balance of those with PD as the signals to the ankle muscles are restored. These studies will provide valuable direction for future research and therapeutic development of PD-associated posture impairment, which could significantly improve quality of life for people with PD. 

 “This award provides the unique opportunity to explore the potential contributions of non-dopaminergic pathways to the abnormal muscle activation patterns observed in people with PD, and to conduct exploratory experiments to test the efficacy of using vagus nerve stimulation to upregulate these pathways, improve muscle activation, gait and postural control,” said Dr. MacKinnon. 

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.  

Raise Awareness

Básicos de los medicamentos para el Parkinson

Parkinson's Medication

La medicación desempeña un papel fundamental en el tratamiento de la enfermedad de Parkinson (EP), pero es sólo una parte de un plan de cuidados más amplio.  

El siguiente artículo se basa en una Charla con Expertos - Expert Briefing de la Parkinson's Foundation donde el Dr. Danny Bega explora cómo encajan los medicamentos en el cuidado integral y holístico del Parkinson. El Dr. Bega tiene una maestría en Ciencias, es profesor adjunto de Neurología, director médico y director del programa de residencia en Neurología del Centro de la Enfermedad de Parkinson y Trastornos del Movimiento de la Northwestern University Feinberg School of Medicine, un Centro de Excelencia de la Parkinson’s Foundation. También es director de los programas de las enfermedades de Huntington y Wilson en Northwestern. 

Comprender la conexión entre la dopamina y el Parkinson 

El Parkinson es un trastorno progresivo relacionado con la disminución de los niveles de dopamina, una sustancia química cerebral que influye en el movimiento, la memoria y muchos otros procesos vitales del organismo. Otras sustancias químicas del cerebro, como la norepinefrina y la serotonina, también pueden verse afectadas en la enfermedad de Parkinson e influir en los síntomas.  

A medida que avanza el Parkinson, el número de células cerebrales que producen dopamina sigue disminuyendo y las células restantes luchan por almacenar y liberarla. Esto provoca lentitud de movimientos, temblores, rigidez y otros síntomas motores. También puede causar diversos síntomas no motores, como estreñimiento, pérdida del olfato y cambios en el pensamiento

Manejo del Parkinson’s 

El Parkinson es una enfermedad compleja. No existe un tratamiento estándar. Sin embargo, los medicamentos —junto con el ejercicio, la atención integral, una dieta nutritiva y prácticas de atención plena— pueden controlar los síntomas del Parkinson y ayudarle a vivir bien.  

Establecer una rutina de ejercicio poco después del diagnóstico puede ayudar a ralentizar la progresión de la enfermedad y mejorar el movimiento, la fuerza, el equilibrio y el estado de ánimo. También puede ayudarle a dormir mejor. Mantenerse social e interactuar puede reducir la sensación de soledad.  

Su equipo de atención es igualmente importante. Busque profesionales médicos expertos en Parkinson, incluyendo un neurólogo, un terapeuta del habla y el lenguaje, un fisioterapeuta y un terapeuta ocupacional, un trabajador social y otros profesionales de la salud, para que le ayuden a controlar los síntomas de la EP. No deje de acudir a las revisiones periódicas. 

El papel de los medicamentos 

La mayoría de los medicamentos para el Parkinson mejoran los síntomas aumentando la dopamina en el cerebro o actuando como la dopamina. La levodopa es el fármaco más eficaz para tratar los síntomas del Parkinson. En el transcurso del Parkinson, la mayoría de las personas tomarán levodopa en algún momento.  

La ansiedad y la depresión también pueden ser frecuentes en el Parkinson y afectar al bienestar incluso más que los síntomas motores. Tratar estos síntomas mediante una combinación de medicamentos, como un ISRS, un IRSN o la mirtazapina, —un antidepresivo tricíclico—, junto con terapia, control del estrés y mantener la actividad física, puede reducir la discapacidad significativamente.  

Las personas recién diagnosticadas de Parkinson a menudo se preguntan cuándo deben empezar a tomar la medicación. Los estudios demuestran que esperar no tiene beneficios. La mayoría de los médicos concuerdan en que debe empezar a tomar la medicación cuando los síntomas se vuelvan molestos.  

Dado que no cada persona experimenta la EP de forma única, los tratamientos varían de una persona a otra, al igual que el ritmo de progresión. Sin embargo, conocer los estadios típicos del Parkinson puede ayudarle a anticiparse a los cambios: 

  • En los primeros cinco años después del diagnóstico, es posible que los síntomas no afecten su vida diaria significativamente. Su médico podría recomendarle un ensayo clínico. La participación en la investigación del Parkinson podría darle acceso temprano a nuevos tratamientos, mejorar la atención y sentar las bases para una cura.  

  • En un plazo de uno a diez años, conforme los síntomas empiezan a interferir con las actividades, la mayoría de las personas con Parkinson pueden esperar una respuesta duradera y constante a la medicación.  

  • Entre cinco y 20 años después del diagnóstico, al cerebro le resulta cada vez más difícil conservar dopamina. La respuesta de su cuerpo a la levodopa puede volverse más corta y menos eficaz. Esto puede provocar fluctuaciones motoras: periodos en "on", cuando la medicación funciona bien, y periodos en "off", cuando la medicación deja de hacer efecto y los síntomas reaparecen. Es importante trabajar de cerca con su médico para ajustar el tratamiento y encontrar lo que mejor se adapte a usted. 

  • Después de 10 o más años de vivir con Parkinson, las personas pueden experimentar problemas más importantes. Algunas personas pueden desarrollar importantes problemas de memoria y pensamiento. Problemas de equilibrio, caídas y congelamiento (la incapacidad temporal para moverse) también puede volverse un problema. Su médico puede hablarle de ajustes de la medicación o terapias farmacológicas o mandarlo a ver a un profesional médico adecuado para sus necesidades, que puede ser un neuropsicólogo, un psiquiatra, un terapeuta del habla y el lenguaje o un terapeuta ocupacional. 

Tipos de medicamentos utilizados en el Parkinson 

Es frecuente que las personas con Parkinson tomen una variedad de medicamentos, en distintas dosis y momentos del día, para manejar los síntomas. Esto puede incluir: 

Agonistas de la dopamina: al principio, los fármacos que estimulan la dopamina en el cerebro, como el pramipexol, el ropinirol y la rotigotina, a menudo pueden tratar los síntomas motores del Parkinson. Los agonistas de la dopamina presentan menos riesgo de discinesias, movimientos erráticos involuntarios que suelen comenzar tras unos años de tratamiento con levodopa.  

Los efectos secundarios pueden incluir náuseas, mareos, somnolencia, confusión y trastornos del control de los impulsos, como compras compulsivas, juegos de azar, comer en exceso y los impulsos sexuales. Los estudios muestran que un 28% de las personas con Parkinson dejan de tomar agonistas de la dopamina debido a los efectos secundarios, mientras que un 40% necesita añadir otra medicación en un plazo de dos años. 

Levodopa: la levodopa, el fármaco más eficaz para los síntomas motores del Parkinson, sustituye a la dopamina en el cerebro. Suele administrarse en combinación con el fármaco carbidopa para reducir las náuseas, un efecto secundario frecuente. Tomar levodopa con las comidas también puede reducir las náuseas, pero las proteínas pueden interferir en la eficacia del fármaco. Alrededor de un 2% de las personas dejan de tomar levodopa debido a los efectos secundarios, mientras que un 15% necesita añadir otra medicación a los dos años.  

Las discinesias, también relacionadas con la levodopa, pueden controlarse a menudo mediante un ajuste de la dosis o mediante tratamiento directo, utilizando un medicamento llamado amantadina. Funciona bloqueando el NMDA, una sustancia química que provoca movimientos extras. La amantadina de liberación inmediata también se utiliza a veces sola para los síntomas motores del Parkinson. Existe un mayor riesgo de confusión y alucinaciones con el uso de amantadina en personas de más de 75 años. También puede asociarse a hinchazón de piernas, alteraciones de la piel y otros efectos secundarios.  

Anticolinérgicos: Los medicamentos trihexifenidilo y benztropina se utilizan a veces para mejorar el temblor o las distonías (calambres dolorosos y sostenidos). Actúan bloqueando la acetilcolina, una sustancia química del cerebro relacionada con el movimiento. Sin embargo, su uso debe evitarse en personas de 70 años o más debido al riesgo de confusión y alucinaciones. Los anticolinérgicos también pueden asociarse a visión borrosa, sequedad de boca, estreñimiento y retención urinaria. 

Algunos de los medicamentos que su médico podría considerar para mejorar los efectos de la levodopa son: 

Inhibidores de la MAO-B: los inhibidores de la monoaminooxidasa B rasagilina, selegilina y safinamida ponen más dopamina a disposición del cerebro. Estos medicamentos pueden utilizarse solos o en combinación con la levodopa para aumentar su eficacia. Los inhibidores de la MAO-B suelen tolerarse bien, pero un 70% de las personas que los toman solos para el Parkinson necesitarán añadir otra medicación a los dos años. 

Inhibidores de la COMT: medicamentos como la entacapona y la opicapona aumentan la levodopa disponible en el cerebro al bloquear la enzima catecol-O-metil transferasa.  

Antagonista del receptor A2A: la istradefilina, un antagonista de la adenosina A2A, bloquea la adenosina en los receptores A2A del cerebro para reducir el tiempo en "off" de la levodopa. 

La levodopa inhalada se utiliza a menudo con la levodopa, según sea necesario, para el tiempo en "off" repentino. La apomorfina inyectable también puede utilizarse a demanda, para el alivio en tiempos en "off". Ambos medicamentos pueden aumentar el riesgo de discinesias. 

Es importante trabajar con su médico para encontrar el equilibrio adecuado para usted. Su médico puede aumentar o disminuir su dosis de levodopa con base en sus síntomas. Por ejemplo, el temblor, la rigidez o los problemas de movilidad podrían beneficiarse de un aumento de la levodopa. Sin embargo, las alucinaciones, la confusión y la baja presión arterial podrían mejorar con una disminución de la levodopa. 

También existen estrategias y medicamentos para controlar el babeo, el goteo nasal, los problemas de sueño, los problemas intestinales, los cambios en el pensamiento y otros desafíos del Parkinson. 

¿Qué pasa si no funciona la levodopa? 

Si está tomando levodopa pero no obtiene beneficios, hable con su médico. Estas son algunas preguntas que puede hacer: 

  • ¿El síntoma que le molesta no responde bien a la levodopa? ¿Podría estar relacionado con otro problema de salud?  

  • ¿Puede haber algo que esté interfiriendo en la absorción de la medicación? Algunas personas experimentan menos beneficios cuando toman levodopa con una comida alta en proteínas. 

También es importante discutir si es necesario ajustar la dosis. Por ejemplo, los efectos del Sinemet, una forma de levodopa, sólo duran poco tiempo: a los 90 minutos, la mitad ha desaparecido. Su médico puede ajustar el horario y la dosis de levodopa, utilizar una formulación de acción más prolongada o recomendar tomar la medicación 30 minutos antes o 60 minutos después de comer. 

Terapias avanzadas 

Si se vuelve difícil controlar las fluctuaciones motoras ajustando la medicación oral, existen otras opciones para mejorar la absorción de la medicación y reducir el tiempo en "off":  

  • La terapia con Duopa suministra carbidopa-levodopa en gel directamente al intestino a través de un tubo colocado quirúrgicamente.  

  • La terapia con foscarbidopa y foslevodopa (Vyalev) utiliza una bomba para administrar de forma constante una forma de levodopa bajo la piel a través de un pequeño tubo llamado cánula. Se utiliza una aguja para colocar la cánula. 

  • La terapia continua con apomorfina (Onapgo) utiliza una bomba para administrar apomorfina de forma continua a través de una fina aguja colocada bajo la piel.  

Estos medicamentos requieren ajustes en el estilo de vida, instrucción para su uso y un compromiso con el buen cuidado de la piel para reducir el riesgo de irritación e infecciones. 

Otras opciones además de la medicación 

En ocasiones, los síntomas de Parkinson más avanzados pueden beneficiarse de otras estrategias de tratamiento, como la estimulación cerebral profunda (ECP, o DBS, por sus siglas en inglés), que consiste en implantar quirúrgicamente un generador de impulsos eléctricos conectado a electrodos colocados en el cerebro para tratar los síntomas motores del Parkinson y algunos síntomas no motores.  

La ECP podría ser considerada para alguien que:  

  • vive con la enfermedad de Parkinson clásica  

  • tiene síntomas que responden a la levodopa  

  • experimenta frecuentes fluctuaciones motoras y temblores, a pesar de una dosificación constante de la medicación 

  • tiene discinesias molestas 

Tras la ECP, muchas personas pueden reducir su medicación y seguir experimentando una reducción de los síntomas de la EP. La reducción de la dosis de medicamento puede llevar a menos discinesias. 

El ultrasonido focalizado, una terapia no invasiva, no requiere una incisión quirúrgica. Durante el procedimiento, se dirigen ondas sonoras de alta frecuencia a una zona específica del cerebro relacionada con el temblor para aliviar el temblor de la enfermedad de Parkinson. A diferencia de la terapia de ECP, que es ajustable y reversible, los cambios por ultrasonido focalizado son permanentes. 

Si tiene preguntas acerca de las opciones de tratamiento de la EP, comuníquese con nuestra Línea de Ayuda al 1-800-4PD-INFO (473-4636) opción 3 para español o en Helpline@Parkinson.org

Aprenda más 

Explore nuestros recursos acerca de medicamentos para tratar los síntomas del Parkinson:  

My PD Story

Versees Headshot
Researchers

Wim Versées, PhD

2025 Impact Award 

Designing Nanobodies that Stabilize Dysfunctional Proteins in Parkinson’s 

The most common genetic risk factor associated with Parkinson’s disease (PD) lies in the GBA1 gene. Research from the Parkinson’s Foundation genetics study, PD GENEration, has found the GBA1 gene is present in 5-10% of people with the disease. GBA1 provides the instructions to make a protein called glucocerebrosidase (GCase), which plays an important role in the waste recycling compartment of the cell, known as lysosomes.  Variants linked to PD produce unstable or less active versions of GCase.  As a result, cells lose part of their cleanup ability, leading to a buildup of harmful proteins such as alpha-synuclein. 

Wim Versées, PhD, recipient of a Parkinson’s Foundation Impact Award, has discovered a set of small proteins called “nanobodies” that attach to and stabilize these fragile forms of GCase, restoring their functionality in cells where they are needed most.  

Most previous research tried to stabilize GCase using small molecule “chaperones”. These compounds could bind and protect the protein but are often attached to the protein’s active site — the very region needed for its normal function, blocking its activity.  The nanobodies, by contrast, stabilize GCase by binding to a previously unexplored site far away from the active site, preserving its natural role.  

Think of mutant GCase as a fragile vase you want delivered safely to your home. One way to protect it during shipping is to fill it with solid material. That will prevent it from breaking, but once it arrives you can no longer use it to hold flowers. This is what happens when molecules bind the active site. Nanobodies, instead, act by binding or wrapping on the outside of the vase. They keep it intact while still allowing it to hold flowers.  

Wim at Work

Supported by the Parkinson’s Foundation Impact Award, Dr. Versées, and his lab at the Flanders Institute for Biotechnology in Belgium, will run a battery of biochemical experiments to hone the design of GCase-stabilizing nanobodies. First, he will use state-of-the-art molecular imaging techniques to see exactly where these nanobodies stick to GCase and how it affects the protein. This information will help Dr. Versées and his team identify which set of nanobodies are the best suited for clinical use and how he can further improve their effectiveness.  

Collaborating with Steven Ballet, PhD, at Vrije Universiteit Brussel, they will also design so-called “peptidomimetics” that are inspired by the nanobodies and have similar GCase-stabilizing features. Since these are much smaller, they can be more easily delivered to the correct cells in the brain, acting as prototypes for future therapeutics. 

Finally, working with Nicoletta Plotegher, PhD, at the University of Padova in Italy, Dr. Versées will test the effectiveness of these nanobodies and peptidomimetics in PD-simulated cells in the lab. Monitoring to what extent the mutant GCase proteins are stabilized and activated with these treatments will validate their potential for future research and their potential as a future treatment. 

Excited by this support, Dr. Versées said “Receiving this award from the Parkinson’s Foundation is both a personal honor and a meaningful endorsement of our research. If successful, this strategy could lead to a new class of molecular chaperones that more effectively target the underlying molecular causes of Parkinson’s, opening new therapeutic avenues for people living with GBA1-associated PD.” 

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers

My PD Story

Lauren Hammer headshot
Researchers

Lauren Hammer, MD, PhD

2025 Stanley Fahn Junior Faculty Award 

Investigating Which Brain Signals Best Guide Adaptive Deep Brain Stimulation 

Deep brain stimulation (DBS) is a promising treatment option for those with Parkinson’s disease (PD) when medications begin to lose their effectiveness. For DBS, electrodes are implanted into the brain that deliver controlled electrical stimulation that counteracts the PD symptoms. 

Most DBS systems are designed to deliver constant, consistent stimulation based on settings set and updated by physicians during checkups. However, a newer version called adaptive DBS (aDBS), recently approved by the FDA for clinical use, monitors brain signals associated with PD symptoms in real time and adjusts stimulation automatically. This ability to auto-adjust stimulation has the potential to enhance DBS efficiency and minimize side effects, improving quality of life for those that use it. 

Lauren Hammer, MD, PhD, recipient of a Parkinson’s Foundation Stanley Fahn Junior Faculty Award, is working to make aDBS even more effective by determining which types of brain signals offer the best information on how to adjust stimulation in response to symptoms. Current aDBS technology monitors low-frequency brain waves called “beta” signals, but Dr. Hammer believes that higher frequency “entrained-gamma” signals may be better for predicting and controlling PD symptoms. 

 “This research aims to advance deep brain stimulation for Parkinson’s disease by identifying the most effective neural signal to guide adaptive DBS,” said Dr. Hammer. 

From her lab at the University of Pennsylvania, a Parkinson’s Foundation Center of Excellence, Dr. Hammer will first run an in-laboratory assessment where people with PD perform various movement tasks while their brain signals are monitored. This will provide data as to which type of signal — beta or entrained-gamma — offers a more accurate reflection for when PD symptoms like involuntary movements are occurring. 

Dr. Hammer will then take a small group of people with DBS for their PD and upgrade them to aDBS for an at-home study. After participants are programmed for aDBS stimulation using both beta signals and entrained-gamma signals, they will switch weekly between these settings, recording how well their symptoms are controlled at home.   

At the end of the trial, Dr. Hammer and her team will have data to suggest which signal type guided the best aDBS experience for different types of people with PD.  

When asked what this support means to her and her research goals, Dr. Hammer said “Receiving this award is an incredible honor and an important milestone in my journey to improve the lives of people with Parkinson’s disease. This research could support expanding the set of neural signals used for clinical aDBS, enabling more effective and personalized treatment.” 

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers

Back to Top